In recent years, an increasingly more in depth understanding of tumor metabolism in
tumorigenesis, tumor growth, metastasis, and prognosis has been achieved. The broad …

Background Chemotherapy is a first-line treatment for advanced and metastatic bladder
cancer, but the unsatisfactory objective response rate to this treatment yields poor 5-year …

Background Invasion and metastasis are the main causes of unfavourable prognosis in
patients diagnosed with bladder cancer. The efficacy of immunotherapy in bladder cancer …

Introduction and objective Muscle-invasive urothelial bladder cancer (MIBC) is associated
with limited response rates to systemic therapy, risk of recurrence and death. Tumor …

Abstract Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized the
management of locally advanced or metastatic urothelial carcinoma. Strikingly, compared to …

Bladder cancer (BLCA) is more common in men but more aggressive in women. Sex-based
differences in cancer biology are commonly studied using a murine model with BLCA …

Urological cancers are considered as life-threatening diseases around the world. Bladder
cancer is one of the most malignant urological tumors with high mortality and morbidity …

Background: Tumor microenvironment (TME) takes a non-negligible role in the progression
and metastasis of bladder urothelial carcinoma (BLCA) and tumor development could be …

Context Polyporus polysaccharide (PPS), the leading bioactive ingredient extracted from
Polyporus umbellatus (Pers.) Fr.(Polyporaceae), has been demonstrated to exert anti …

The increased activity of the mTOR pathway in bladder cancer has been extensively studied,
but no satisfactory mTOR inhibitor has been found in bladder cancer. The role of AZD8055 …